-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

603. Oncogenes and Tumor Suppressors: Poster III

Program: Oral and Poster Abstracts
Type: Poster
Hematology Disease Topics & Pathways:
ALL, AML, apoptosis, Biological, HSCs, Leukemia, Diseases, Lymphoma (any), cell regulation, Combinations, Therapies, MDS, Non-Hodgkin Lymphoma, Biological Processes, DLBCL, MPN, Immune Disorders, Technology and Procedures, Cell Lineage, Lymphoid Malignancies, Clinically relevant, genomics, Myeloid Malignancies, NK cells, hematopoiesis, Proliferative disorders, RNA sequencing, pathogenesis, WGS, pathways
Monday, December 7, 2020: 7:00 AM-3:30 PM

Constance Baer, PhD1, Shunsuke Kimura, MD, PhD2*, Ilaria Iacobucci3*, David J Feith, BS, PhD4*, Wencke Walter, PhD1*, Manja Meggendorfer, PhD1, Thomas L. Olson, PhD5*, Aakrosh Ratan, PhD6*, Martha-Lena Müller, PhD1*, Mitra Rana7*, Chunxu Qu, PhD2*, Ravi Kalathur7*, Claudia Haferlach, MD1, Wolfgang Kern, MD1, Thomas P. Loughran Jr., MD4, Charles G Mullighan, MBBS, MD2 and Torsten Haferlach, MD1

1MLL Munich Leukemia Laboratory, Munich, Germany
2Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN
3Department of Pathology, St. Jude Children´s Research Hospital, Memphis, TN
4Department of Medicine, Division of Hematology/Oncology, University of Virginia Cancer Center, Charlottesville, VA
5Department of Medicine, Division of Hematology/Oncology, University of Virginia, Charlottesville, VA
6Center for Public Health Genomics, University of Virginia, Charlottesville, VA
7Department of Structural Biology, St. Jude Children´s Research Hospital, Memphis, TN

Monique Chavez, BS1, Erica Barnell, BS2*, Malachi Griffith, PhD3*, Zachary Skidmore4*, Obi Griffith3*, Ling Tian, PhD5* and Lukas D Wartman, MD6

1Department of Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, MO
2Washington University in St. Louis School of Medicine, Saint Louis, MO
3McDonnell Genome Institute, Department of Medicine, Washington University School of Medicine, Saint Louis, MO
4Washington University In St Louis, Saint Louis, MO
5Department of Medicine, Division of Oncology, Washington University School of Medicine, SAINT LOUIS, MO
6Department of Medicine, Division of Oncology, Washington University School of Medicine, Saint Louis, MO

Rasoul Pourebrahim, MD, PhD1*, Rafael Heinz Montoya, BS1*, Zoe Alaniz1*, Lauren B Ostermann, BS1*, Hung Alex Luong1*, Joseph D. Khoury, MD2 and Michael Andreeff, MD, PhD1

1Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
2Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, TX

Gisele Olinto Libanio Rodrigues, MSc1*, Julie Hixon1*, Hila Winer1*, Erica Matich1*, Caroline Andrews2*, Sarah Cramer3*, Wenqing Li1* and Scott Durum1*

1National Cancer Institute, National Institutes of Health, Frederick, MD
2Charles River Laboratories, Frederick
3StageBio company, Frederick, MD

Yang Han, MM1,2*, Ya Zhang, MD1,2*, Juan Yang, PhD1,3*, Jiarui Liu1,4*, Tan Sang1,2*, Shunfeng Hu, MM1,2*, Xinting Hu, MM1,2* and Xin Wang, MD, PhD1,2

1Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China
2Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China
3Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong, China
4Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China

Yuki Nishida, MD, PhD1, Jo Ishizawa, MD, PhD2, Edward Ayoub, PhD, MS, BSc2*, Rafael Heinz Montoya, BS2*, Vivian Ruvolo, MS2*, Kensuke Kojima, MD, PhD3*, Naval Daver, MD4, Arnaud Lesegretain5*, Sharon Shacham, PhD, MBA6* and Michael Andreeff, MD, PhD2

1Section of Molecular Hematology and Therapy, Department of Leukemia, MD Anderson Cancer Center, Houston, TX
2Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
3Department of Hematology, Kochi University Hospital, Nankoku, Japan
4Department of Leukemia, The University of Texas, M.D. Anderson Cancer Center, Houston, TX
5Daiichi Sankyo, Inc., Basking Ridge, NJ
6Karyopharm Therapeutics Inc., Natick, MA

Carmelo Gurnari, MD1,2*, Vera Adema, PhD2*, Hassan Awada, MD2, Simona Pagliuca, MD2,3, Cassandra M Kerr, MS2*, Sunisa Kongkiatkamon, MD2*, Thomas Laframboise, PhD4*, Valeria Visconte, PhD2, Maria Teresa Voso, MD1, Mikkael A. Sekeres, MD, MS2,5, Hetty E. Carraway, MD, MBA2,6, Torsten Haferlach, MD7 and Jaroslaw P. Maciejewski, MD, PhD8

1Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy
2Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
3Université de Paris, Paris, France
4Genetics and Genome Sciences Department, Case Western Reserve University, Cleveland, OH
5Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
6Department of Hematology and Medical Oncology, Leukemia Program, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
7MLL Munich Leukemia Laboratory, Munich, Germany
8Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

*signifies non-member of ASH